Background: Hidradenitis suppurativa (HS) is associated with various somatic and psychiatric comorbidities. Data regarding comorbidities in young patients with HS are sparse.
H idradenitis suppurativa (HS) typically begins in the second or third decade of life. 1, 2 The mean time from the onset of symptoms to a confirmed diagnosis has been variously reported as 7 to 14 years. 3, 4 Several comorbidities are associated with HS, including diabetes, metabolic syndrome, psychiatric disorders, and inflammatory arthritis. [5] [6] [7] [8] HS markedly impairs the patient's quality of life, especially in those whose symptoms have an early onset. 9, 10 HS is considered rare in children, with prepubescent onset estimated to occur in 2% of patients. 2 In a Dutch study, however, 7.7% of patients with HS reported having symptoms before their thirteenth birthday. 11 Patients with early-onset HS tend to have a family history and are likely to develop more widespread, but not necessarily more severe, disease than those with adult-onset HS. 11, 12 When early-and adult-onset HS were compared in adult patients, no differences were found in the prevalence of associated acne, rheumatoid arthritis, or inflammatory bowel disease (IBD). 11 A few case reports indicate a link between prepubertal HS and premature adrenarche, adrenal hyperplasia, or metabolic syndrome. [13] [14] [15] Few data are available on HS in pediatric populations, 16 and the comorbidity profile of HS in childhood and adolescence has not been properly explored. The aim of this national registrye based case-control study was to elucidate the characteristics of comorbid diseases in patients with HS who were younger than 18 years.
METHODS

Populations and databases
This was a retrospective matched case-control database study of all Finnish pediatric patients with HS diagnosed between 1987 and 2014. The statutory Finnish Care Register for Health Care was queried to identify patients who had received a diagnosis of HS (International Classification of Diseases [ICD] , Ninth Revision [ICD-9], code 7058C and ICD, Tenth Revision [ICD-10], code L73.2) at least once during the study period. The study and the control groups were formed as described earlier. 8 Records of patients age 5 to younger than 18 years at the time of diagnosis were included in the study because the youngest child with HS described in the literature was 5 years old 2 and infantile forms of HS resolve early in childhood. 13, 17 Four controls per HS case were randomly selected and matched by age and sex with melanocytic nevi cases. Diagnoses of comorbid diseases based on ICD-9 and ICD-10 codes were gathered for case and control patients from the same registry first before they had reached the age of 18 years and again before they had reached the age of 23 years.
Statistical analyses
The characteristics of the study population are presented as proportions and means. A conditional logistic regression model was used to characterize proportional exposure between patients with HS and controls for different diseases. Statistical analyses were performed by using the SAS software package (version 9.4, SAS Institute, Inc, Cary, NC).
RESULTS
Characteristics of young patients with HS and melanocytic nevi
The original query yielded 4381 case patients with HS. 8 Of these, 153 ranged in age from 5 and younger than 18 years at diagnosis. For the present study, this subgroup was designated as those with youth-onset HS (yHS). The original query found 43,248 case patients with benign melanocytic nevi, 8475 of whom were age 5 and to younger than 18 years. After age and sex matching, 612 subjects formed the control group for the present study. The demographics of these subjects are summarized in Table I .
In general, 34.0% of patients with yHS had at least 1 of the prespecified somatic comorbidities and 15.7% had at least 1 of the psychiatric comorbidities. Of subjects with yHS, 9.2% had at least 1 of each type of comorbidity (Fig 1) .
Somatic and psychiatric comorbidities in young patients with HS
Comparisons between the case patients and controls demonstrated that the yHS group had substantially higher somatic and psychiatric morbidity (Tables II and III) at the age of 18 years. To clarify the possibility of comorbidities accumulating with increasing age, the prevalence of comorbidities was analyzed again when subjects were 23 years of age. No significant differences in patterns of somatic comorbidity were found between the ages of 18 and 23 (data not shown). However, when the prevalence of each psychiatric disorder was evaluated again at the age of 23 years, 23.5% of patients in the yHS group and 8.7% of nevi controls had received at least 1 psychiatric diagnosis (Table III and This study demonstrates the psychiatric and somatic comorbidities of hidradenitis suppurativa in young patients.
d
Young patients with hidradenitis suppurativa need care for the comorbidities of HS, which may accumulate over time.
comorbidities, which occur in as many as 34.0% of patients with HS, psychiatric comorbidities are common in this patient population from adolescence. Psychiatric disorders were the most common single group of comorbidities; they were present in 15.7% of the yHS population at the age of 18 years. Notably, the proportion had increased to 23.5% by the time they had reached the age of 23 years. This result may be an underestimate, because approximately half the patients with HS studied had not reached the age of 23 by the end of the follow-up period. The prevalence of major depression increased from 8.5% to 15.7% in the HS group with a 5-year advance in age. In contrast, the proportion of patients in the control group with a diagnosis of depression showed only a slight increase (from 3.4% to 4.9%) with the same age advance. The prevalence of anxiety in the HS group did not increase as substantially (from 5.9% to 9.2%), but because anxiety often develops into depression in younger people, 18 it is possible that some earlier cases of anxiety were later recognized as depression.
Previously, by utilizing the same registry, we found that at least 1 psychiatric disorder was diagnosed in up to 24.1% of all patients with HS. Thus, mental disorders are even more common in patients with HS than in patients with psoriasis. 8 At 23.5%, the rate of psychiatric disorders in the yHS group at the age of 23 years almost reached the level in the overall HS population. The frequency of depression at the age of 23 in this cohort of patients with yHS was 15.7%, which is comparable to the 15.3% we found in the overall HS population.
In the present study, IBDs were significantly more common in the yHS group than in the control group, indicating that IBDs are associated with HS from an early age. A recent Danish study found an association between HS and IBDs in an adult population, although the frequency of IBDs in the HS population was fairly low, at 2.1%. 19 Finland has one of the highest frequencies of IBDs in the world (approximately 0.8% of the general population). 20 In our study population IBDs were particularly common in the yHS group, affecting 3.3% of patients. The peak incidence of IBDs typically occurs between the ages of 20 and 40 years, although the incidence in the pediatric population has been increasing. 21 Studies suggest a female predominance in Crohn's disease, 21 which could partially explain the finding since most of the patients in the yHS group were girls. The onset of IBD early in life may be associated with a more severe and complicated disease course and possibly even with an elevated risk for intestinal cancer. 22 It is therefore important for clinicians to consider that children with HS may also have IBD and to suggest appropriate screening measures.
We found that inflammatory joint diseases, including spondyloarthropathies, were significantly more frequent in the yHS group than in the controls. Spondyloarthropathies are known to be associated with HS, particularly in male patients. 23 Because this association is already strong in young patients with HS, it is important for physicians to look for musculoskeletal symptoms and possible signs of inflammatory joint disease.
A diagnostic code of acne was recorded in 13.7% of young patients with HS compared with in 0.7% of the control group. This points to a likelihood of more severe acne in HS, although a misdiagnosis of acne youth-onset HS may have been made in some patients with HS, which could lead to an overestimation of acne in the yHS group. In our study, 5.9% of the patients in the yHS group had a diagnosis of obesity, which is a significantly greater proportion than in the control group. In adult HS populations, rates of obesity have varied from 12% to 88%. 24 It is probable that 5.9% is an underestimation because physicians might have hesitated to record the diagnostic code for obesity if the weight problem was not striking for fear of stigmatizing the young patient. Type 1 diabetes and hypertension were more common in the yHS group than in the control group, but the difference was not significant.
During the study period, Down syndrome occurred in approximately 0.13% of live births in Finland. 25 In our study, 4.6% of patients with yHS (7 of 153) had Down syndrome, suggesting a clear association between these 2 conditions. The odds ratio for this outcome could not be calculated because no patient in the control group had Down syndrome. Because the onset of HS symptoms happens at an earlier age in individuals with Down syndrome, 26 it may have been over-represented in our young HS population, and thus the prevalence of 4.6% may not reflect the true rate in the entire population of patients with HS. Thyroid disorders were more common in patients with HS than in controls, as has also been found in an adult population. 7 This result was not considered significant because a thyroid disorder had been diagnosed in 2 of 7 of our patients with yHS and Down syndrome (28.6%), and thyroid diseases are more frequent in individuals with Down syndrome. 27 On the other hand, although obesity is more common in Down syndrome, obesity was not diagnosed in any patient with both yHS and Down syndrome. Consequently, the association between HS and obesity seems to be apparent in childhood. No psychiatric disorder was diagnosed in any individual with Down syndrome in the yHS group by the age of 23. Thus, our findings regarding the prevalence of mental disorders could not be confounded by Down syndrome, which has been associated with psychiatric vulnerability in adulthood. 28 There are case reports of early-onset HS associated with certain hormonal imbalances and metabolic syndrome, 13-15 but we did not find any patient with premature adrenarche or adrenal hyperplasia. Metabolic syndrome was diagnosed in 3 individuals in the HS group versus in 1 in the control group. The prevalence of metabolic syndrome might be an underestimation because the diagnostic code is relatively new and has been utilized in Finland only since the late 1990s.
Although our study utilizes one of the largest nationwide yHS cohorts ever studied, it contains no more than 153 young case patients with a diagnosis of HS, which may cause low statistical power. Another weakness is that in a register-based nationwide study it is not possible to verify the accuracy of the HS diagnosis or the ICD-9 or ICD-10 diagnoses of comorbidities. The data in the Finnish Care Register for Health Care have been shown to be accurate and can be considered reliable. 29 In addition, previous studies from the United States have shown that HS diagnosis in hospital registers has a reasonably high positive predictive value. 7, 30 On the basis of our nationwide registry study, young patients with HS carry a considerable risk for many somatic and psychiatric comorbidities and the prevalence of mental disorders increases rapidly during young adulthood. Therefore, young patients need substantial care not only for their HS lesions but J AM ACAD DERMATOL VOLUME 79, NUMBER 3 also for the comorbidities of HS, which may accumulate over time. CI, Confidence interval; Nevi, melanocytic nevi; OR, odds ratio; yHS, youth-onset hidradenitis suppurativa.
Fig 2.
The cumulative prevalence of any psychiatric disorder in the youth-onset hidradenitis suppurativa and melanocytic nevi groups.
